327 related articles for article (PubMed ID: 21175227)
1. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.
Magro F
BioDrugs; 2010 Dec; 24 Suppl 1():1-2. PubMed ID: 21175227
[No Abstract] [Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
4. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
6. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
Rebelo A; Leite S; Cotter J
BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
[TBL] [Abstract][Full Text] [Related]
7. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
[No Abstract] [Full Text] [Related]
8. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
Peyrin-Biroulet L
Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
[No Abstract] [Full Text] [Related]
9. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease.
Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP
J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656
[No Abstract] [Full Text] [Related]
10. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
[TBL] [Abstract][Full Text] [Related]
11. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
Flamant M; Bourreille A
Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
13. [Patient information. Biological agents in inflammatory bowel disease].
Van Domselaar M
Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
[No Abstract] [Full Text] [Related]
14. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment.
Bergamaschi G; Di Sabatino A; Albertini R; Ardizzone S; Biancheri P; Bonetti E; Cassinotti A; Cazzola P; Markopoulos K; Massari A; Rosti V; Porro GB; Corazza GR
Haematologica; 2010 Feb; 95(2):199-205. PubMed ID: 19815838
[TBL] [Abstract][Full Text] [Related]
15. [Natural history of inflammatory bowel disease].
Matsui T
Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1172-82. PubMed ID: 17675819
[No Abstract] [Full Text] [Related]
16. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
Lopez-Sanroman A; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
[No Abstract] [Full Text] [Related]
17. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
18. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab.
Fidalgo C; Calado J; Cravo M
BioDrugs; 2010 Dec; 24 Suppl 1():15-7. PubMed ID: 21175229
[TBL] [Abstract][Full Text] [Related]
19. The management of fistulizing oral Crohn's disease with infliximab.
Staines KS; Green R; Felix DH
J Oral Pathol Med; 2007 Aug; 36(7):444-6. PubMed ID: 17617840
[TBL] [Abstract][Full Text] [Related]
20. [Perspectives in inflammatory bowel diseases treatment].
Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
